ARSA — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL17384095	0.64	1/20
SCHEMBL64776	0.58	1/20
SCHEMBL33372528	0.58	1/20
SCHEMBL893374	0.57	1/20
SCHEMBL30702421	0.57	1/20
SCHEMBL3081576	0.56	1/20
SCHEMBL17384169	0.53	1/20
SCHEMBL17384172	0.53	1/20
SCHEMBL7915211	0.50	1/20
SCHEMBL21190538	0.50	1/20
SCHEMBL22260258	0.50	1/20
SCHEMBL7577681	0.49	1/20
SCHEMBL3584746	0.49	1/20
SCHEMBL5470220	0.49	1/20
SCHEMBL30154375	0.49	1/20
SCHEMBL7912329	0.48	1/20
SCHEMBL22609991	0.48	1/20
SCHEMBL11480829	0.47	1/20
SCHEMBL2957612	0.47	1/20
SCHEMBL3192410	0.47	1/20

Clinical trials — most relevant to ARSA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India	PHASE4	COMPLETED
Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy	PHASE4	COMPLETED
OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)	PHASE3	ACTIVE_NOT_RECRUITING
Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)	PHASE2/PHASE3	COMPLETED
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment	PHASE2/PHASE3	COMPLETED
An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)	PHASE3	COMPLETED
Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation	PHASE2	COMPLETED
Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic Leukodystrophy	PHASE1/PHASE2	COMPLETED
A Study in MPS VI to Assess Safety and Efficacy of Odiparcil	PHASE2	COMPLETED
Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)	PHASE1/PHASE2	COMPLETED
Gene Therapy in Patients With Mucopolysaccharidosis Disease	PHASE1/PHASE2	COMPLETED
A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy	PHASE2	ACTIVE_NOT_RECRUITING
Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)	PHASE1/PHASE2	COMPLETED
A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)	PHASE2	COMPLETED
Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy	PHASE1/PHASE2	UNKNOWN
Gene Therapy for Metachromatic Leukodystrophy (MLD)	PHASE1/PHASE2	COMPLETED
An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy	PHASE1/PHASE2	COMPLETED
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome	PHASE1	COMPLETED
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers	PHASE1	COMPLETED
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)	nan	COMPLETED
Imaging Study of the White Matter Lesions in Children With Metachromatic Leucodystrophy	nan	COMPLETED
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD	nan	RECRUITING
Biomarker for Maroteaux-Lamy Disease (BioMaroteaux)	nan	WITHDRAWN
Direct Lentiviral Injection Gene Therapy for MLD	nan	RECRUITING
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Chest Wall Deformities in Children - Epidemiological Data	nan	COMPLETED
A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)	nan	COMPLETED
Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome	nan	AVAILABLE
A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)	nan	COMPLETED
Returning Genetic Results on Arsenic Susceptibility	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ARSA binder may also engage these)

Protein	Name	Similarity
Q08DD1	—	1.000	Q08DD1 →
P50428	—	1.000	P50428 →
P15589	—	0.986	P15589 →
P51689	—	0.982	P51689 →
Q3TYD4	—	0.981	Q3TYD4 →
Q32KJ9	—	0.974	Q32KJ9 →
P50429	—	0.972	P50429 →
Q5FYA8	—	0.971	Q5FYA8 →
P15848	—	0.971	P15848 →
P51690	—	0.971	P51690 →
Q96EG1	—	0.970	Q96EG1 →
P50427	—	0.970	P50427 →
Q60HH5	—	0.970	Q60HH5 →
P14000	—	0.968	P14000 →
P50430	—	0.968	P50430 →
P54793	—	0.967	P54793 →
P21836	—	0.967	P21836 →
P33727	—	0.967	P33727 →
P23795	—	0.966	P23795 →
P37136	—	0.966	P37136 →
O97524	—	0.965	O97524 →
P51688	—	0.965	P51688 →
O18835	—	0.965	O18835 →
GAA	Lysosomal alpha-glucosidase	0.964	landscape →
O62763	—	0.964	O62763 →
P51840	—	0.963	P51840 →
ACHE	Acetylcholinesterase	0.963	landscape →
Q29499	—	0.963	Q29499 →
Q32KH8	—	0.963	Q32KH8 →
P51839	—	0.963	P51839 →